P75.22 Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis

Programmed death 1(PD-1)/programmed ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs) has shown remarkable efficacy in the treatment of cancer. The predictive value PD-L1 expression for ICIs advanced non-small cell lung cancer (NSCLC) raise wide attention, also with some controversies. We combined existing data by meta-analysis to analyze patients different levels, and provide a basis selection best benefited patients. Databases such as PubMed, Cochrane Library, Embase database, clinicaltrial.gov major international conferences ASCO, ESMO, WCLC were searched select qualified literatures according inclusion exclusion criteria. divided all into three groups PD-L1≥50%, 1%∼49% PD-L1<1%. All analyses used program RevMan5.3, levels compared chemotherapy outcome measures OS, PFS ORR. Finally, 11 from 10 randomized controlled trials total 6122 included study, including 3349 group 2828 group. results follows: 1. In NSCLC therapy improved OS (P<0.00001), (P<0.0001), ORR (P=0.003) chemotherapy. 2. 1%∼49%, associated longer than (P=0.002), consistent second or later line but not first therapy. But (P=0.8) (P=0.05) no statistical significances these 3. PD-L1<1%, (P=0.001) chemotherapy, (P=0.97) (P=0.34) significances. level may have NSCLC. Patients PD-L1≥50% could be recipients ICIs. PD-L1<1% had benefits therapy, benefit, more evidence is needed first-line treatment.